Observations on the Efficacy of Dog Days' Acupoint Application in Treating Allergic Rhinitis
10.13460/j.issn.1005-0957.2017.05.0588
- VernacularTitle:"""三伏天""穴位贴敷治疗变应性鼻炎疗效观察"
- Author:
Hongli ZHANG
;
Minghui ZHAO
;
Yetao HU
;
Lixin FU
- Keywords:
Allergic rhinitis;
Acupoint application;
Acupoint therapy;
VAS score;
Symptom score;
Sign score;
Adverse reaction;
Relapse rate
- From:
Shanghai Journal of Acupuncture and Moxibustion
2017;36(5):588-593
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of dog days' acupoint application in treating allergic rhinitis and assess its safety.Methods Two hundred and forty-nine patients were randomly allocated to a dog days' acupoint application group of 166 cases and a placebo group of 83 cases. The two groups were received treatment at the first day of the first, second and last periods of the hot season The dog days' acupoint application group received acupoint application of Chinese herbal medicine and the placebo group, acupoint application of non-medicinal placebo. In the two groups, the symptoms and signs were scored and the VAS score was recorded before and after treatment and during the follow-up period, and adverse reactions and relapses were observed and the clinical therapeutic effect of acupoint application and its safety were assessed after treatment and during the follow-up period.Results The total efficacy rate was 69.8% in the dog days' acupoint application group and 44.4% in the placebo group. The therapeutic effect was significantly better in the dog days' acupoint application group than in the placebo group (P<0.01). The totalefficacy rate was 89.4% at the 6-month follow-up and 90.7% at the 12-month follow-up in the dog days' acupoint application group and 4.9% and 1.2% in the placebo group. The long-term therapeutic effect was significantly better in the dog days' acupoint application group than in the placebo group (P<0.01). In the dog days' acupoint application group, the symptom score, the sign score and the VAS score were significantly lower after treatment and during the follow-up period than before treatment (bothP<0.01). In the placebo group, those scores only had significant pre-/post-treatment differences (P<0.01). There were statistically significant differences in the symptom score, the sign score and the VAS score between the two groups at different times. The adverse reaction rate was 4.3% in the dog days' acupoint application group and 2.5% in the placebo group; there was no statistically significant difference between the two groups (P>0.05). The relapse rate was 46,6% at the 6-month follow-up and 62.1% at the 12-month follow-up in the dog days' acupoint application group and 85.2% and 95.1% in the placebo group; there were statistically significant differences between the two groups (P<0.01).Conclusions Dog days' acupoint application has better short-term and long-term therapeutic effect on allergic rhinitis with a low relapse rate and high safety.
